[Cerebral toxoplasmosis complicating an allograft with hematopoietic stem cells from peripheral blood].
We report the occurrence of a cerebral toxoplasmosis 52 days after a non-myeloablative allogeneic stem cell transplantation as treatment for acute myeloid leukemia.
Dugauquier
C
C
Département de Médecine Générale, CHU de Liège, Belgique.
Bataille
Y
Y
Willems
E
E
Frère
P
P
De Prijck
B
B
Beguin
Y
Y
Baron
F
F
D000818:Animals; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D017809:Fatal Outcome; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016867:Immunocompromised Host; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011739:Pyrimethamine / Q000627:therapeutic use; D013411:Sulfadiazine / Q000627:therapeutic use; D014122:Toxoplasma / Q000302:isolation & purification*; D016781:Toxoplasmosis, Cerebral / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous
D000981:Antiprotozoal Agents; D013411:Sulfadiazine; D011739:Pyrimethamine